Lexeo Therapeutics Inc (NASDAQ: LXEO) on Friday, plunged -14.52% from the previous trading day, before settling in for the closing price of $7.78. Within the past 52 weeks, LXEO’s price has moved between $7.47 and $22.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 19.69%. The company achieved an average annual earnings per share of 75.24%. With a float of $21.71 million, this company’s outstanding shares have now reached $26.65 million.
Considering the fact that the conglomerate employs 58 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Lexeo Therapeutics Inc (LXEO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lexeo Therapeutics Inc is 32.52%, while institutional ownership is 73.89%. The most recent insider transaction that took place on Nov 11 ’24, was worth 19,557. In this transaction Chief Executive Officer of this company sold 2,500 shares at a rate of $7.82, taking the stock ownership to the 120,695 shares. Before that another transaction happened on Oct 10 ’24, when Company’s Chief Executive Officer sold 5,000 for $8.10, making the entire transaction worth $40,496. This insider now owns 120,695 shares in total.
Lexeo Therapeutics Inc (LXEO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.24% per share during the next fiscal year.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
Lexeo Therapeutics Inc (LXEO) is currently performing well based on its current performance indicators. A quick ratio of 5.95 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.84, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.89 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Compared to the last year’s volume of 0.25 million, its volume of 1.64 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 11.40%. Additionally, its Average True Range was 0.93.
During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.35% in the past 14 days, which was higher than the 95.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.01, while its 200-day Moving Average is $12.89. Nevertheless, the first resistance level for the watch stands at $7.52 in the near term. At $8.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.82. If the price goes on to break the first support level at $6.22, it is likely to go to the next support level at $5.78. Now, if the price goes above the second support level, the third support stands at $4.92.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats
Market capitalization of the company is 187.95 million based on 33,066K outstanding shares. Right now, sales total 0 K and income totals -66,390 K. The company made 0 K in profit during its latest quarter, and -21,240 K in sales during its previous quarter.
